Monday’s Midday Movers: Whiting Petroleum Corp (WLL), Novavax (NVAX), Continental Resources (CLR), ACADIA Pharmaceuticals Inc (ACAD), Encana Corp (ECA)
By Carrie Williams So far Monday, September 16, NASDAQ is up 1.18% and the S&P is up 0.28%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Whiting Petroleum Corp (WLL – Research Report), Novavax (NVAX – Research Report), Continental Resources (CLR – Research Report), ACADIA Pharmaceuticals Inc (ACAD – Research Report) and Encana Corp (ECA – Research Report).
Whiting Petroleum Corp is up 20.85% in midday trading to $11.42. Shares opened today at $9.45. The company has a 52-week low of $6.00 and a 52-week high of $55.17. On the Street’s front, the average 12-month analyst price target for the stock is $15.77, marking a 66.88% potential upside from current levels. In a report released today, KeyBanc analyst Leo Mariani upgraded WLL to Buy. Separately, on September 10, Merrill Lynch’s Asit Sen downgraded the stock to Hold and has a price target of $11. In the last 30 days, insiders have sold $2,992 worth of WLL shares.
Novavax is up 11.64% in midday trading to $7.10. Shares opened today at $6.36. The company has a 52-week low of $4.01 and a 52-week high of $51.60. On the Street’s front, the average 12-month analyst price target for the stock is $26.88, marking a 322.64% potential upside from current levels. In a report released today, B.Riley FBR analyst George Zavoico maintained a Buy rating on NVAX, with a price target of $35, which implies an upside of 450% from current levels. In the last 30 days, insiders have sold $31.91K worth of NVAX shares and purchased $32.4K worth of NVAX shares. Over the last 3 months, the insider sentiment on Novavax has been negative based on 7 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.
Continental Resources is up 10.2% in midday trading to $39.21. Shares opened today at $35.58. The company has a 52-week low of $27.54 and a 52-week high of $71.95. On the Street’s front, the average 12-month analyst price target for the stock is $49.89, marking a 40.22% potential upside from current levels. In a report issued on August 21, Guggenheim analyst Subash Chandra reiterated a Buy rating on CLR, with a price target of $50, which implies an upside of 41% from current levels. Separately, on July 18, Susquehanna’s Biju Perincheril maintained a Hold rating on the stock and has a price target of $42.
See today’s analyst top recommended stocks >>
ACADIA Pharmaceuticals Inc is up 10.15% in midday trading to $44.28. Shares opened today at $40.20. The company has a 52-week low of $13.87 and a 52-week high of $44.35. On the Street’s front, the average 12-month analyst price target for the stock is $51.22, marking a 27.41% potential upside from current levels. In a report issued on September 13, Leerink analyst Marc Goodman upgraded ACAD to Buy, with a price target of $50, which represents a potential upside of 24% from where the stock is currently trading. Separately, on September 9, Stifel Nicolaus’ Paul Matteis maintained a Hold rating on the stock and has a price target of $39. In the last 30 days, insiders have sold $2.45M worth of ACAD shares. Over the last 3 months, the insider sentiment on ACADIA Pharmaceuticals Inc has been negative based on 9 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.
See today’s analyst top recommended stocks >>
Encana Corp is up 8.05% in midday trading to $5.71. Shares opened today at $5.28. The company has a 52-week low of $3.93 and a 52-week high of $13.61. On the Street’s front, the average 12-month analyst price target for the stock is $6.32, marking a 19.70% potential upside from current levels. In a report issued on August 13, Citigroup analyst Brian Downey maintained a Buy rating on ECA, with a price target of $10, which implies an upside of 89% from current levels. Separately, on July 30, Suntrust Robinson Humphrey’s Neal Dingmann initiated coverage with a Hold rating on the stock and has a price target of $4. In the last 30 days, insiders purchased $111.8K worth of ECA shares. Over the last 3 months, the insider sentiment on Encana Corp has been positive based on 54 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.